Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: ST-segment elevation myocardial infarction complicated by cardiogenic shock (n=360235). Intervention: Impella vs. Intra-aortic balloon pump (IABP). Primary outcome: Short-term mortality (30-day and in-hospital) (OR 1.68, 95% CI 1.49-1.89).

Q: What does this research mean for the field?

In patients with STEMI complicating cardiogenic shock, Impella is associated with a significantly higher risk of short-term mortality and adverse events compared with intra-aortic balloon pump. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Boyu Guan; Xinsheng Li; Jiahua Zhang; Dongyuan Yu; Yujian Peng; Haichen Lv; Zhujing Hao

doi:10.3389/fcvm.2026.1782887

October 28, 2026Frontiers in Cardiovascular MedicineOpen Access

Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis

View Full Paper

Ask AI

Bookmark

Share

Key result

Impella is linked to ~68% higher short-term mortality vs. IABP in STEMI cardiogenic shock.

OR 1.68
95% CI 1.49-1.89
n=360,235

Why the study?

STEMI with cardiogenic shock carries high mortality, yet optimal treatment with mechanical circulatory support devices, vasoactive agents, and inotropic agents remains uncertain in this population.

What is the comparative efficacy and safety of mechanical circulatory support devices (such as IABP, Impella, and ECMO) in reducirg mortality and adverse events in adult patients with STEMI complicated by cardiogenic shock?

Key Points

To systematically evaluate and compare the efficacy and safety of mechanical circulatory support devices in adult patients with ST-elevation myocardial infarction complicated by cardiogenic shock.
Conducted a network meta-analysis (PROSPERO CRD420251002524) searching six databases through September 2026 for randomized and observational studies.
Synthesized data from 22 studies (2 randomized controlled trials and 20 cohort studies) comprising a pooled population of 360,235 predominantly older (mean age 67 years) and male (65%) patients.
Based on observational evidence, Impella was associated with a significantly higher risk compared with intra-aortic balloon pump (IABP) for short-term mortality (OR 1.68, 95% CI 1.49–1.89), bleeding (OR 1.62, 95% CI 1.49–1.75), stroke (OR 2.67, 95% CI 1.01–7.03), and acute kidney injury (OR 1.55, 95% CI 1.10–2.18).
Compared with control, Impella significantly increased stroke risk (OR 4.37, 95% CI 3.74–5.11), while randomized trial evidence showed higher bleeding risk with Impella versus control (RR 2.06, 95% CI 1.15–3.66) and versus IABP (OR 5.50, 95% CI 1.03–29.45).

Study Design

Type

Meta-Analysis (n=360,235)

Blinding

Open-label

Multicenter

Yes

Structured PICO

What is the comparative efficacy and safety of mechanical circulatory support devices (such as IABP, Impella, and ECMO) in reducirg mortality and adverse events in adult patients with STEMI complicated by cardiogenic shock?

P

Population

360,235 predominantly male (65%) older adults (mean age 67 years) with STEMI complicated by cardiogenic shock across 22 studies (97.9% United States-based), evaluated for short-term and 1-year outcomes.

I

Intervention

Mechanical circulatory support (MCS) devices, vasoactive agents, and inotropic agents, including intra-aortic balloon pump (IABP), Impella, extracorporeal membrane oxygenation (ECMO), ECMO + Impella, IABP + ECMO, and rhBNP + IABP.

C

Comparator

Control (standard care) and head-to-head comparisons between different MCS regimens (e.g., Impella vs. IABP, ECMO vs. IABP).

O

Outcome

Short-term mortalityhard clinical

Main Result

Odds Ratio: 1.68 (95% CI 1.49–1.89)

In patients with STEMI complicated by cardiogenic shock, Impella is associated with higher risks of short-term mortality, bleeding, stroke, and acute kidney injury compared to IABP in observational studies, suggesting IABP may be a safer initial mechanical support option when hemodynamically feasible.

Limitations

Predominance of observational data (20 cohort studies vs. 2 RCTs) limits causal inference and introduces confounding by indication and selection bias
Over 97% of included patients were from the United States, creating potential overlap across shared administrative databases and limiting international generalizability
Exclusion of mixed AMI trials that did not report separate subgroup data for STEMI patients
Potential violations of the network meta-analysis transitivity assumption due to heterogeneity in shock severity, timing of device support, and baseline comorbidities
Lack of sufficient subgroup reporting in primary studies precluded formal stratified analyses by renal impairment or multivessel disease
Broad confidence intervals in several comparisons due to small sample sizes in specific treatment nodes
Only one pharmacological agent (rhBNP) had available evidence, preventing a comprehensive comparison of vasoactive and inotropic agents
Combination therapy outcomes were seldomly reported in original research
Observational studies may be heavily influenced by patient selection and salvage use
Substantial heterogeneity in primary analyses requiring exclusion of influential studies in sensitivity analyses

Implication

Impella may increase short-term mortality versus IABP in STEMI shock; leaves open optimal device selection pending randomized trials.

Abstract

Background ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock carries high mortality, yet optimal treatment remains uncertain in this distinct patient population. The aim of this study is to systematically evaluate and compare the efficacy of mechanical circulatory support (MCS) devices, vasoactive agents, and inotropic agents in the management of critical adult patients with STEMI complicating cardiogenic shock. Methods A network meta-analysis (PROSPERO CRD420251002524) was conducted, with systematic searches of six databases (Embase, Web of Science, PubMed, and Cochrane, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform) from inception to March 2025 for randomized and observational studies. We also updated the search to September 2026 using the same search strategy. Results Data from 22 studies (pooled n = 360,235) revealed a predominantly male (65%), older adult population (mean age 67 years), US-based (97.9%) population with hypertension, hyperlipidemia, diabetes or heart failure. Compared with intra-aortic balloon pump (IABP), based on observational evidence, Impella was associated with a significantly higher risk of short-term mortality (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.49–1.89), bleeding (OR 1.62, 95% CI 1.49–1.75), stroke (OR 2.67, 95% CI 1.01–7.03), AKI (OR 1.55, 95% CI 1.10–2.18), and AKI requiring dialysis (OR 1.67, 95% CI 1.50–1.87). Compared with control, Impella significantly increased the risk of stroke (OR 4.37, 95% CI 3.74–5.11). Randomized controlled trials (RCTs) have also supported an increased bleeding risk with Impella compared with IABP or standard care. Conclusion For STEMI patients with cardiogenic shock, IABP may be considered as a mechanical support option when hemodynamically feasible. By contrast, Impella has been associated with an unfavorable risk-benefit profile in this population in observational studies, which may be heavily influenced by patient selection and salvage use. Therefore, its application warrants careful consideration if escalation is necessary. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251002524 , PROSPERO CRD420251002524.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guan et al. (2026) conducted a meta-analysis in ST-segment elevation myocardial infarction complicated by cardiogenic shock (n=360,235). Impella vs. Intra-aortic balloon pump (IABP) was evaluated on Short-term mortality (30-day and in-hospital) (OR 1.68, 95% CI 1.49-1.89). Impella was associated with a significantly higher risk of short-term mortality compared with intra-aortic balloon pump (OR 1.68, 95% CI 1.49-1.89) in patients with STEMI and cardiogenic shock.

synapsesocial.com/papers/6ae4338fd9418cd7c8f465bd https://doi.org/10.3389/fcvm.2026.1782887

View Full Paper

Ask AI

Bookmark

Share

Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading